Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Gains from Investment Securities: 2018-2019

Historic Gains from Investment Securities for DiaMedica Therapeutics (DMAC) over the last 1 years, with Dec 2019 value amounting to $71,000.

  • DiaMedica Therapeutics' Gains from Investment Securities rose 9.23% to $71,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $75,000, marking a year-over-year change of. This contributed to the annual value of $30,000 for FY2024, which is 400.00% up from last year.
  • DiaMedica Therapeutics' Gains from Investment Securities amounted to $71,000 in Q4 2019, which was up 7,000.00% from $1,000 recorded in Q3 2019.
  • In the past 5 years, DiaMedica Therapeutics' Gains from Investment Securities ranged from a high of $71,000 in Q4 2019 and a low of $1,000 during Q2 2019.
  • Over the past 2 years, DiaMedica Therapeutics' median Gains from Investment Securities value was $20,500 (recorded in 2018), while the average stood at $29,833.
  • Examining YoY changes over the last 5 years, DiaMedica Therapeutics' Gains from Investment Securities showed a top increase of 9.23% in 2019 and a maximum decrease of 94.87% in 2019.
  • Quarterly analysis of 2 years shows DiaMedica Therapeutics' Gains from Investment Securities stood at $65,000 in 2018, then grew by 9.23% to $71,000 in 2019.
  • Its Gains from Investment Securities was $71,000 in Q4 2019, compared to $1,000 in Q3 2019 and $1,000 in Q2 2019.